Company intelligence / Profile preview

Hangzhou Yuyuan Bioscience Technology Co., Ltd.

Hangzhou, Zhejiang Province, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

The company's lead product nolasiban (OBE001) is in Phase 3 clinical development. It is a novel, oral oxytocin receptor antagonist being developed for improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization.

Therapeutic areas: Women's Health
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

follitropin alfa

Phase 3

Indications: In vitro fertilization, Assisted reproductive technology

Partnerships

ObsEva (sublicense agreement for nolasiban)

Beyond the preview

Go deeper on Hangzhou Yuyuan Bioscience Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Yuyuan Bioscience Technology Co., Ltd..

Explore the full profile